Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(04): 283-289
DOI: 10.1055/s-0042-1750015
Original Article

Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges

Amit Bhoil
1   Department of Nuclear Medicine, The Royal Liverpool University Hospital National Health Service Trust, Liverpool, United Kingdom
,
Phei Shan Chuah
1   Department of Nuclear Medicine, The Royal Liverpool University Hospital National Health Service Trust, Liverpool, United Kingdom
,
Nagabhushan Seshadri
1   Department of Nuclear Medicine, The Royal Liverpool University Hospital National Health Service Trust, Liverpool, United Kingdom
,
Sobhan Vinjamuri
1   Department of Nuclear Medicine, The Royal Liverpool University Hospital National Health Service Trust, Liverpool, United Kingdom
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Aim Radium-223 has been the first-approved targeted Alpha therapy agent. We retrospectively assessed different factors influencing the overall survival (OS) and patient management.

Setting and Design Thirty-two metastatic castration-resistant prostate cancer (mCRPC) patients' hematological parameters, number of cycles, performance status, and toxicities were evaluated for OS. Radium 223 dichloride (Radium-223) was administered every 4 weeks for a maximum of six cycles. Primary and secondary end points were OS, progression free survival (PFS), therapy toxicities, change in performance status, biochemical response, and skeletal-related events (SREs).

Materials and Methods Patients' median age was 77 years (range: 57–90 years) and median follow-up was 399 days (range: 5–1,761 days). A total of 163 cycles were administered in 32 patients, with 4 or less cycles in 8 patients (25%) and 5 or more cycles in 24 patients (75%). Among eight patients with 4 or less cycles, three patients died, of which two patients died due to neutropenic sepsis.

Statistical Analysis Mann–Whitney test was used to compare the cycle groups; Spearman's correlation coefficient was used to see the relation of different variables with OS. Log rank test was used for group comparison while Kaplan–Meier survivorship was used for OS.

Results Statistical correlation was seen between the number of cycles (p=0.037) and hemoglobin (p=0.028). Kaplan–Meier OS (p=0.038) was correlated with the number of cycles (≤ 4 cycles and ≥ 5 cycles). OS was 173 days in patients with one to four cycles, 226 days in five cycles, and 493 days in six cycles. Myelosuppression leading to stopping of full six cycles was seen in 7 of 32 patients (22%) and significantly correlated to inferior OS (p=0.048).

Conclusion Higher number of Radium-223 cycles was seen to be associated with better OS. Prior myelosuppression was associated with poor OS. Patients with better hematological profile were more likely to complete the maximum number of the cycles with a better OS.

Keywords

Radium-223 - overall survival - myelosuppression - toxicity - health economics

Note

The manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author believes that the manuscript represents honest work, if that information is not provided in another form.




Publication History

Article published online:
02 September 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (05) E359-E386
    CrossrefPubMedGoogle Scholar
  • 2 McMahon GC, Brown GA. Successfully integrating radium Ra 223 dichloride injection into a urology practice. Rev Urol 2017; 19 (04) 248-251
    Google Scholar
  • 3 Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011; 65 (11) 1180-1192
    CrossrefPubMedGoogle Scholar
  • 4 Cookson MS, Roth BJ, Dahm P. et al. Castration-resistant prostate cancer: AUA Guideline. J Urol 2013; 190 (02) 429-438
    CrossrefPubMedGoogle Scholar
  • 5 Sathiakumar N, Delzell E, Morrisey MA. et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011; 14 (02) 177-183
    CrossrefPubMedGoogle Scholar
  • 6 Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 1998; –1999 17 (04) 331-336
    CrossrefPubMedGoogle Scholar
  • 7 Basch E, Loblaw DA, Oliver TK. et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014; 32 (30) 3436-3448
    CrossrefPubMedGoogle Scholar
  • 8 Den RB, George D, Pieczonka C, McNamara M. Ra-223 treatment for bone metastases in castrate-resistant prostate cancer: practical management issues for patient selection. Am J Clin Oncol 2019; 42 (04) 399-406
    CrossrefPubMedGoogle Scholar
  • 9 Hegemann M, Bedke J, Stenzl A, Todenhöfer T. Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther Adv Urol 2017; 9 (3-4): 81-88
    CrossrefPubMedGoogle Scholar
  • 10 Fizazi K, Carducci M, Smith M. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377 (9768): 813-822
    CrossrefPubMedGoogle Scholar
  • 11 Saad F, Gleason DM, Murray R. et al; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94 (19) 1458-1468
    CrossrefPubMedGoogle Scholar
  • 12 Brito AE, Etchebehere E. Radium-223 as an approved modality for treatment of bone metastases. Semin Nucl Med 2020; 50 (02) 177-192
    CrossrefPubMedGoogle Scholar
  • 13 Boni G, Mazzarri S, Cianci C. et al. 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: real-world experience. Tumori 2018; 104 (02) 128-136
    CrossrefPubMedGoogle Scholar
  • 14 Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?. Clin Cancer Res 2006; 12 (20, pt. 2): 6250s-6257s
    CrossrefPubMedGoogle Scholar
  • 15 Henriksen G, Breistøl K, Bruland OS, Fodstad Ø, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002; 62 (11) 3120-3125
    PubMedGoogle Scholar
  • 16 Hoskin P, Sartor O, O'Sullivan JM. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014; 15 (12) 1397-1406
    CrossrefPubMedGoogle Scholar
  • 17 Umeweni N, Knight H, McVeigh G. NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases. Lancet Oncol 2016; 17 (03) 275-276
    CrossrefPubMedGoogle Scholar
  • 18 Parker C, Nilsson S, Heinrich D. et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (03) 213-223
    PubMedGoogle Scholar
  • 19 Saad F, Carles J, Gillessen S. et al; Radium-223 International Early Access Program Investigators. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016; 17 (09) 1306-1316
    CrossrefPubMedGoogle Scholar
  • 20 Gazzilli M, Durmo R, Cossalter E. et al. Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single-centre experience. Nucl Med Commun 2020; 41 (04) 300-307
    CrossrefPubMedGoogle Scholar
  • 21 Persidis A. Cancer multidrug resistance. Nat Biotechnol 1999; 17 (01) 94-95
    CrossrefPubMedGoogle Scholar
  • 22 Leisser A, Nejabat M, Hartenbach M. et al. Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment. Oncotarget 2018; 9 (22) 16197-16204
    CrossrefPubMedGoogle Scholar
  • 23 McKay RR, Jacobus S, Fiorillo M. et al. Radium-223 use in clinical practice and variables associated with completion of therapy. Clin Genitourin Cancer 2017; 15 (02) e289-e298
    CrossrefPubMedGoogle Scholar
  • 24 Vogelzang NJ, Coleman RE, Michalski JM. et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin Genitourin Cancer 2017; 15 (01) 42-52.e8
    CrossrefPubMedGoogle Scholar
  • 25 Renzulli II JF, Collins J, Mega A. Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer. J Multidiscip Healthc 2015; 8: 279-286
    CrossrefPubMedGoogle Scholar
  • 26 Du Y, Carrio I, De Vincentis G. et al. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2017; 44 (10) 1671-1678
    CrossrefPubMedGoogle Scholar
  • 27 Dizdarevic S, Jessop M, Begley P, Main S, Robinson A. 223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice. Eur J Nucl Med Mol Imaging 2018; 45 (13) 2264-2273
    CrossrefPubMedGoogle Scholar
  • 28 Jadvar H, Challa S, Quinn DI, Conti PS. One-year postapproval clinical experience with radium-223 dichloride in patients with metastatic castrate- resistant prostate cancer. Cancer Biother Radiopharm 2015; 30 (05) 195-199
    PubMedGoogle Scholar
  • 29 Ahmadzadehfar H, Essler M, Rahbar K, Afshar-Oromieh A. Radionuclide therapy for bone metastases: utility of scintigraphy and PET imaging for treatment planning. PET Clin 2018; 13 (04) 491-503
    CrossrefPubMedGoogle Scholar
  • 30 Parker C, Nilsson S, Heinrich D. et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (03) 213-223
    Google Scholar
  • 31 Parikh S, Murray L, Kenning L. et al. Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer. Clin Oncol (R Coll Radiol) 2018; 30 (09) 548-555
    CrossrefPubMedGoogle Scholar
  • 32 Sartor O, Coleman R, Nilsson S. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014; 15 (07) 738-746
    CrossrefPubMedGoogle Scholar
  • 33 Zhang I, Gilbo P, Kohn N, Cox B. Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer. Pract Radiat Oncol 2018; 8 (06) 452-457
    CrossrefPubMedGoogle Scholar
  • 34 Dakin H, Devlin N, Feng Y, Rice N, O'Neill P, Parkin D. The influence of cost-effectiveness and other factors on nice decisions. Health Econ 2015; 24 (10) 1256-1271
    CrossrefPubMedGoogle Scholar
  • 35 White BE, Mujica-Mota R, Snowsill T, Gamper EM, Srirajaskanthan R, Ramage JK. Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. Rev Endocr Metab Disord 2021; 22 (03) 647-663
    CrossrefPubMedGoogle Scholar
  • 36 Valderrama A, Bilir SP, Wehler EA. et al. Estimating the Economic impact of radium Ra 223 dichloride (Radium-223) in treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. Value Health 2014; 17 (03) PA74
    CrossrefGoogle Scholar
  • 37 Saad F, Sternberg CN, Mulders PFA, Niepel D, Tombal BF. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. Cancer Treat Rev 2018; 68: 25-37
    CrossrefPubMedGoogle Scholar